Emerging developments and trends in advanced lung cancer

Gems from the WCLC20 poster hall which may make an impact

February 9, 2021

A look at the exon 20 landscape in lung cancer

A look at the exon 20 insertion landscape - all to play for!

February 4, 2021

What happens when genomics, KRAS, and IO converge in lung cancer?

Genomic analysis in IO trials is on the increase - what happens when PD-1 and KRAS collide?

February 2, 2021

A critical look at the Amgen sotorasib data in KRAS G12C mutated lung cancers

Discussion of the Amgen sotorasib data presented at WCLC20 in Singapore

February 1, 2021

How will AI impact oncology R&D?

Some intriguing convergence from two recent conferences offers new insights from an AI perspective

January 28, 2021

AACR Preview 2 – Pathways to Success in Targeted Therapies

A look at a wide array of targets, modalities, new agents and companies through the lens of targeted therapies

April 16, 2020

The many faces of lung cancer

WCLC 2019 Review – Part 3 - Targeted Therapy Highlights excluding KRASi

September 12, 2019

New developments in immunotherapy from WCLC19

Summary of IO highlights and lowlights from WCLC 2019

September 10, 2019

Targeting KRAS – Highlights from WCLC 2019

Barcelona – Gosh, what a weekend chock full of lung cancer data at the World Congress on Lung Cancer…

September 9, 2019

A look at Amgen’s early oncology pipeline

Amgen have a large early phase 1 oncology pipeline including bispecifics, BiTEs, a CAR and small molecules. What can we learn from recent data presented?

July 18, 2019

An update on key SCLC trials

A look at the CheckMate-331 and CheckMate-451 study and other SCLC trials

October 12, 2018

WCLC2018 Roundup of key lung cancer data

After the WCLC2018 preview, what does the data actually teach us? A round up and commentary on 16 key trials

September 25, 2018

Preview of WCLC 2018 – what’s new in lung cancer?

What to watch out for at WCLC2018 in Toronto later this month

September 6, 2018